← Leaderboards
Robert A. Mitchell
University Of Louisville
$6,052,736
Attributed
$6,253,936
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $545.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,253,936 · 6
By mechanism
R01$5,447,509 · 4
P20$404,027 · 1
R21$402,400 · 1
Top collaborators
- Ming Song2 shared
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsMalignant NeoplasmsCellsTumorMouse ModelCytokineMigration Inhibitory FactorProteinsIn VivoGrowthBaseResistanceAngiogenesisLaboratoriesReceptorDisease ProgressionFuturePreventLeadCell MotilityLesionIn-MigrationGenetic TranscriptionNeoplasm Metastasis
Grant awards (25)
Immunotherapeutic targeting of MIF-dependent chaperone activity$341,782
R01 · FY2025 · CA · contact PI
Dietary fructose and NASH/HCC progression$182,909
R21 · FY2025 · CA
Immunotherapeutic targeting of MIF-dependent chaperone activity$325,842
R01 · FY2024 · CA · contact PI
Dietary fructose and NASH/HCC progression$219,491
R21 · FY2024 · CA
Immunotherapeutic targeting of MIF-dependent chaperone activity$355,907
R01 · FY2023 · CA · contact PI
Small molecule targeting of MIF as a novel melanoma therapeutic$311,250
R01 · FY2018 · CA · contact PI
Small molecule targeting of MIF as a novel melanoma therapeutic$311,250
R01 · FY2017 · CA · contact PI
Small molecule targeting of MIF as a novel melanoma therapeutic$311,250
R01 · FY2016 · CA · contact PI
Small molecule targeting of MIF as a novel melanoma therapeutic$311,250
R01 · FY2015 · CA · contact PI
Small molecule targeting of MIF as a novel melanoma therapeutic$311,250
R01 · FY2014 · CA · contact PI
Amplification of tumor hypoxic responses by MIF-dependent HIF stabilization$280,014
R01 · FY2013 · CA · contact PI
Amplification of tumor hypoxic responses by MIF-dependent HIF stabilization$297,887
R01 · FY2012 · CA · contact PI
Amplification of tumor hypoxic responses by MIF-dependent HIF stabilization$297,887
R01 · FY2011 · CA · contact PI
Amplification of tumor hypoxic responses by MIF-dependent HIF stabilization$307,100
R01 · FY2010 · CA · contact PI
Amplification of tumor hypoxic responses by MIF-dependent HIF stabilization$307,100
R01 · FY2009 · CA · contact PI
Role of MIF in Rb inactivation and Tumorigenesis$119,591
R01 · FY2009 · CA · contact PI
Role of MIF in Rb inactivation and Tumorigenesis$228,588
R01 · FY2008 · CA · contact PI
Role of MIF in Rb inactivation and Tumorigenesis$228,588
R01 · FY2007 · CA · contact PI
Role of MIF in Rb inactivation and Tumorigenesis$42,939
R01 · FY2007 · CA · contact PI
Role of MIF in Rb inactivation and Tumorigenesis$235,415
R01 · FY2006 · CA · contact PI
Role of MIF in Rb inactivation and Tumorigenesis$40,459
R01 · FY2006 · CA · contact PI
Role of MIF in Rb inactivation and Tumorigenesis$241,080
R01 · FY2005 · CA
COBRE:LOUISVILLE RES FOUND INC: P2: DVMT &TEST OF SMALL MOLECULAR ANTAGONISTS$192,559
P20 · FY2005 · RR
MIF in Rb inactivation and Tumorigenesis$241,080
R01 · FY2004 · CA
DELVELOPMENT AND TEST OF SMALL MOLECULAR ANTAGONISTS$211,468
P20 · FY2004 · RR